Benylin Chesty

To provide nutritional supplementation in individuals with malabsorptive conditions. ADEKs uses water- miscible forms of the fat-soluble vitamins to improve absorption in these individuals. It also provides vitamin C, B complex vitamins, and other vitamins plus zinc to supplement dietary intake.

For nutritional supplementation in individuals with deficient diets or difficulty in absorbing fat-soluble vitamins such as may occur in cystic fibrosis. For use solely under medical supervision.

Acute coronary disease and cardiac asthma. Caution should be observed in patients suffering from hyperthyroidism and/or peptic ulceration. Not to be administered concurrently with alpha and beta-blocking agents.

Many sympathomimetics interact with monoamine oxidase inhibitors, and should not be given to patients receiving such treatment or within 14 days of its termination.

WARNINGS:

should be avoided or used with caution in patients undergoing anaesthesia with cyclopropane, halothane or other halogenated anaesthetics, as it may induce ventricular fibrillation. An increased risk of arrhythmias may also occur if given to patients receiving cardiac glycosides, quinidine, or tricyclic antidepressants. Many sympathomimetics interact with monoamine oxidase inhibitors, and should not be given to patients receiving such treatment or within 14 days of its termination.

Gastro-intestinal side-effects may occur occasionally with Bromhexine (Benylin Chesty) and a transient rise in serum aminotransferase value has been reported.

Orciprenaline (Benylin Chesty) Sulphate, a sympathomimetic may produce a wide range of adverse effects. Central effects include fear, anxiety, restlessness, tremor, insomnia, confusion, irritability, and psychotic states. Appetite may be reduced, and nausea and vomiting may occur.

Cardiac effects include vasoconstriction which may be sufficiently severe to cause gangrene or a rise in blood pressure which may produce cerebral haemorrhage and pulmonary oedema, reflex bradycardia. Stimulation of beta1-adrenergic receptors of the heart may produce tachycardia, cardiac arrhythmias, anginal pain, palpitations, and cardiac arrest; hypotension with dizziness and fainting and flushing may occur.

Other, effects that may occur include difficulty in micturition and urinary retention, dyspnoea, altered metabolism including disturbances of glucose metabolism, sweating and hypersalivation. Headache is also common.